Amoéba Axpera obtains emergency market authorisation in France
Amoéba has received a 120-day emergency market authorisation from the French Ministry of Agriculture for its biocontrol product Axpera to combat downy mildew on grapevines in France. This approval allows large-scale field trials from mid-April to mid-August 2025, covering up to 250 hectares, supported by the French Wine and Vine Institute. The milestone represents another validation of Amoéba's innovative biocontrol application, and while significant sales are not yet expected in 2025, the early market sounding could boost demand in years to come. Meanwhile, the company is awaiting final product evaluation by YE25/early '26. We reiterate our € 1.7 TP and Buy rating.Amoeba SA. Amoeba SA is a France-based company that develops, manufactures and markets biological products. The Company specializes in disruptive biological solutions for the treatment of Legionella, amoeba and biofilm in water. The Company's offering includes products and services, such as: Cleantech biological solution, a patented technological disruptive product with no impact on the environment; amoebic analyses of waters of wet cooling towers (TAR), hot sanitary waters, industrial waters and waters of swimming pools; as well as Legionella tests of industrial waste water, among others. The Company is engaged in various technical, commercial, industrial and investment partnerships.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.